Introduction/Background The incidence of brain metastases (BMs) in ovarian cancer (OC) is ranging from 0.49% to 6.1%. This heterogeneity can be partially explained by diagnostic procedures and treatment improvement, influencing positively on detection and outcome rates. We aimed to analyze patients with BMs from OC in a single center experience and calculate interval between diagnosis of OC and BMs, interval between BMs and data of last contact.

Methodology All women with OC with BMs, who were treated in Oncogynecological Department of N.N. Alexandrov National Cancer Centre of Belarus between January 1980 and December 2022 were retrospectively identified. The main criteria were serous carcinoma, endometrioid carcinoma and clear cell carcinoma and brain metastases. All data and follow-up were taken from medical records and analyzed afterward. Interval between diagnosis of OC and BMs, interval between BMs and data of last contact were studied with the use of Kaplan-Meier curves. The statistical analyses were performed using SPSS statistical software (version 23.0). A two-sided p-value < 0.05 was considered statistically significant.

Results 106 patients with BMs met the inclusion criteria. We divided patients into 4 group: 1 -without any treatment, 2- or surgery or chemotherapy or radiology, 3- combining two methods of treatment (chemotherapy with radiology (CR), chemotherapy with surgery (CS), surgery with radiology (SR)), 4 - surgery combined with radiotherapy and chemotherapy. Median time from development of BMs to last contact date for 1st group was 0 month, for 2nd – 3 months (95% CI [1.93; 10.47]), for 3rd – 11,5 months (95% CI [11.29; 20.27]), for 4th – 28 months (95% CI [21.32; 44.68]). When comparing all medians in pairs, statistically significant differences were noted in each comparison (p< 0.05).

Conclusion The best option for patients with OC with BMs were the application of the multimodal treatment.

Disclosures The authors have nothing to disclose.